Constitutive activation of IKK2/NF-κB impairs osteogenesis and skeletal development

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Swarnkar, Gaurav ^a   Zhang, Kaihua ^a   Mbalaviele, Gabriel ^a   Long, Fanxin ^a   Abu Amer, Yousef ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; ALKALINE PHOSPHATASE; COLLAGEN TYPE 10; COLLAGEN TYPE 2; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN IKK2CA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE STRUCTURE; CARTILAGE CELL; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; EPIPHYSIS; EX VIVO STUDY; HETEROZYGOSITY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEWBORN; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROTEIN EXPRESSION; STROMA CELL; TIBIA; TRABECULAR BONE; VERTEBRA MALFORMATION; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; BONE; CYTOLOGY; ENZYME ACTIVATION; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; BIOMARKERS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; CELL DIFFERENTIATION; CHONDROCYTES; CHONDROGENESIS; ENZYME ACTIVATION; GENE EXPRESSION; I-KAPPA B KINASE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MODELS, BIOLOGICAL; NF-KAPPA B; OSTEOBLASTS; OSTEOGENESIS; PHENOTYPE; STROMAL CELLS;

EID: 84897522219     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091421     Document Type: Article

References (58)

1. Tanaka Y, Nakayamada S, Okada Y (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4: 325-328. (Pubitemid 40873119)
2. Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649. (Pubitemid 36917505)
3. Zaidi M (2007) Skeletal remodeling in health and disease. Nature medicine 13: 791-801.
4. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science (New York, NY) 289: 1508-1514.
5. Cheung WW, Zhan JY, Paik KH, Mak RH (2010) The impact of inflammation on bone mass in children. Pediatric Nephrology: 1-10.
6. Haynes DR (2004) Bone lysis and inflammation. Inflamm Res 53: 596-600.
7. Mundy GR (2007) Osteoporosis and inflammation. Nutr Rev 65: S147-151.
8. Romas E, Gillespie MT (2006) Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin North Am 32: 759-773. (Pubitemid 46590093)
9. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I (2008) Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57: 684-694. (Pubitemid 351579985)
10. Sweeney SE, Firestein GS (2004) Rheumatoid arthritis: regulation of synovial inflammation. The International Journal of Biochemistry & Cell Biology 36: 372-378. (Pubitemid 37542434)
11. Walsh NC, Crotti TN, Goldring SR, Gravallese EM (2005) Rheumatic diseases: the effects of inflammation on bone. Immunological reviews 208: 228-251. (Pubitemid 41746396)
12. Abu-Amer Y (2009) Inflammation, cancer, and bone loss. Current Opinion in Pharmacology 9: 427-433.
13. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 7: 429-442. (Pubitemid 46834849)
14. Horwood N (2008) Lymphocyte-derived cytokines in inflammatory arthritis. Autoimmunity 41: 230-238.
15. Ghishan FK, Kiela PR (2011) Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. American Journal of Physiology - Gastrointestinal and Liver Physiology 300: G191-G201.
16. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, et al. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13: 156-163.
17. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, et al. (2010) Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Annals of the Rheumatic Diseases 69: 2152-2159.
18. Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases. Endocrine Reviews 33: 747-783.
19. Sarahrudi K, Thomas A, Albrecht C, Aharinejad S (2012) Strongly enhanced levels of sclerostin during human fracture healing. Journal of Orthopaedic Research 30: 1549-1555.
20. Siebenlist U, Franzoso G (2001) Structure, regulation and function of NF-kB. Proc Natl Acad Sci U S A 89: 4333-4337.
21. Tak P, Firestein G (2001) NF-kB: a key role in inflammatory diseases. J Clin Invest 107: 7-11. (Pubitemid 32047405)
22. Ting AY, Endy D (2002) SIGNAL TRANSDUCTION: Decoding NF-kB Signaling. Science 298: 1189-1190. (Pubitemid 35285473)
23. Hayden MS, Ghosh S (2004) Signaling to NF-kB. Genes and Development 18: 2195-2224.
24. Karin M, Yamamoto Y, Wang M (2004) The IKK NF-kB system: A treasure trove for drug development. NatRev 3: 17-26. (Pubitemid 38088695)
25. Abu-Amer Y, Faccio R (2006) Therapeutic approaches in bone pathogeneses: targeting the IKK/NF-kB axis. Future Medicine 1: 133-146.
26. Abu-Amer Y, Darwech I, Otero J (2008) Role of the NF-kappaB axis in immune modulation of osteoclasts and bone loss. Autoimmunity 41: 204-211. (Pubitemid 351454990)
27. Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Science's Stke [Electronic Resource]: Signal Transduction Knowledge Environment 2006: re13.
28. Ruocco MG, Karin M (2005) IKK{beta} as a target for treatment of inflammation induced bone loss. Annals of the Rheumatic Diseases 64 Suppl 4: iv81-85. (Pubitemid 41532026)
29. Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu L-C, et al. (2005) IkB kinase-beta, but not IKK-alpha, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201: 1677-1687. (Pubitemid 40721011)
30. Schopf L, Savinainen A, Anderson K, Kujawa J, DuPont M, et al. (2006) IKK beta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis and Rheumatism 54: 3163-3173. (Pubitemid 44622087)
31. Otero JE, Chen T, Zhang K, Abu-Amer Y (2012) Constitutively Active Canonical NF-kappaB Pathway Induces Severe Bone Loss in Mice. PLoS ONE 7: e38694.
32. Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y (2010) IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 25: 1282-1294.
33. Sasaki Y, Derudder E, Hobeika E, Pelanda R, Reth M, et al. (2006) Canonical NF-[kappa]B Activity, Dispensable for B Cell Development, Replaces BAFF-Receptor Signals and Promotes B Cell Proliferation upon Activation. Immunity 24: 729-739. (Pubitemid 43867365)
34. Chang J, Wang Z, Tang E, Fan Z, McCauley L, et al. (2009) Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 15: 682-689.
35. Chang J, Liu F, Lee M, Wu B, Ting K, et al. (2013) NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proceedings of the National Academy of Sciences 110: 9469-9474.
36. Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, et al. (2011) Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. Journal of Clinical Investigation 121: 4685-4699.
37. Cao Q, Kaur C, Wu CY, Lu J, Ling EA (2011) Nuclear factor-kappa β regulates Notch signaling in production of proinflammatory cytokines and nitric oxide in murine BV-2 microglial cells. Neuroscience 192: 140-154.
38. 2-Catenin Function by the IΰB Kinases. Journal of Biological Chemistry 276: 42276-42286.
39. Ovchinnikov DA, Deng JM, Ogunrinu G, Behringer RR (2000) Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. genesis 26: 145-146.
40. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, et al. (2008) Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14: 306-314. (Pubitemid 351347911)
41. Swarnkar G, Sharan K, Siddiqui JA, Mishra JS, Khan K, et al. (2012) A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. Br J Pharmacol 165: 1526-1542.
42. Yao Y, Wang Y (2013) ATDC5: An excellent in vitro model cell line for skeletal development. Journal of Cellular Biochemistry 114: 1223-1229.
43. Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, et al. (2005) TNF-alpha and pathologic bone resorption. Keio J Med 54: 127-131.
44. Schett G, Smolen JS (2005) New insights in the mechanism of bone loss in arthritis. Current Pharmaceutical Design 11: 3039-3049. (Pubitemid 41149939)
45. Pasparakis M (2009) Regulation of tissue homeostasis by NF-B signalling: Implications for inflammatory diseases. Nature Reviews Immunology 9: 778-788.
46. Boyce BF, Yao Z, Xing L (2010) Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci 1192: 367-375.
47. Baker RG, Hayden MS, Ghosh S (2011) NF-ΰB, inflammation, and metabolic disease. Cell Metabolism 13: 11-22.
48. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, et al. (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39: 754-766. (Pubitemid 44311706)
49. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, et al. (2009) The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517-525.
50. WANG S-Y, LIU Y-Y, YE H, GUO J-P, LI R, et al. (2011) Circulating Dickkopf-1 Is Correlated with Bone Erosion and Inflammation in Rheumatoid Arthritis. The Journal of Rheumatology 38: 821-827.
51. Chang J, Liu F, Lee M, Wu B, Ting K, et al. (2013) NF-kappaB inhibits osteogenic differentiation of mesenchymal stem cells by promoting beta-catenin degradation. Proc Natl Acad Sci U S A 110: 9469-9474.
52. Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, et al. (2008) Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Research Reviews 7: 83-105. (Pubitemid 351418294)
53. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, et al. (2010) SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298: E419-428.
54. Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, et al. (2011) Sirt1 is a regulator of bone mass and a repressor of sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152: 4514-4524.
55. Li X, Wang H, Touma E, Rousseau E, Quigg RJ, et al. (2007) Genetic network and pathway analysis of differentially expressed proteins during critical cellular events in fracture repair. Journal of Cellular Biochemistry 100: 527-543. (Pubitemid 46146099)
56. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, et al. (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.[see comment]. Blood 112: 196-207.
57. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, et al. (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. British Journal of Cancer 97: 964-970. (Pubitemid 47519305)
58. Reikerås O, Shegarfi H, Wang JE, Utvåg SE (2005) Lipopolysaccharide impairs fracture healing: An experimental study in rats. Acta Orthopaedica 76: 749-753.